ASCO: Skirmishes Break Out In The Great Lung Cancer Battle

Thumbnail
Thumbnail
Thumbnail

Report Highlights

  • For prescribers, at least, it is becoming ever more important to stay up to date with the numerous subgroups into which first-line NSCLC is being cut.
  • Genetic subtype, histology, patients’ ability to tolerate toxicities, and biomarkers such as PD-L1 status and tumour mutation burden all need to be borne in mind.

The battle for market share in first-line non-small-cell lung cancer has reached fever pitch. As investors’ and doctors’ attention now turns to the annual Asco meeting a de-escalation of hostilities looks unlikely.

Merck & Co’s Keytruda looks increasingly likely to seize the lion’s share of this market. This does not mean that there is no longer anything to play for, but the battle now seems to be turning into a series of skirmishes over ever smaller slices of the pie.

 

Download Report

Vantage logo
Kickstarting ideas
Independent, data-driven daily news and analysis on pharma, biotech and medtech.